KRAS and colorectal cancer: Clinically, when treated with cetuximab, KRAS wild-type colorectal cancers experience on average a tumor decrease of only 41% after 24 weeks of treatment, leaving a significant tumor mass that could potentially develop additional genetic variant alleles associated with resistance.